Linked Life Data

9120545

Source:http://linkedlifedata.com/resource/pubmed/id/9120545

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1997-4-23
pubmed:abstractText
Thirty one patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of carboplatin (CBDCA) and etoposide (VP16) at tumor progression. Carboplatin and etoposide (CE) were given, each at a dose of 100 mg/m2/day from day 1 to 3. The response was evaluated at each course and a minimum of three course was required to definite stable patient. Tolerance was evaluated in 31 patients. None had renal or auditory toxicity. Side effects consisted of grade III hematologic toxicity in 6 patients (19%), and grade III hepatic toxicity in one patient. No grade IV WHO toxicity was observed. All 31 patients could be evaluated for therapeutic response. A partial response was noted in 4 patients during 13, 34 +, 35 + and 51 + weeks. Ten patients had stable disease after a minimum of 3 courses (19 to 37 weeks). The rate of partial response (PR) and stabilisation (S) was 45% (14/31). The median time to tumor progression (MTTP) for responding and stable patients was 28 weeks. The median survival time (ST) for the entire group was 45 weeks and over 51 weeks for PR and S patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0167-594X
pubmed:author
pubmed:issnType
Print
pubmed:volume
32
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
155-60
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study.
pubmed:affiliation
Department of Neurology Hôpital de la Pitté Salpêtrière, Paris, France.
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II